Misconceptions about drug therapies


Both the patients and their families may be concerned because of the many misconceptions about the medication treatment of schizophrenia.


In addition to the side effects, the possibility of becoming addicted may be alarming, as well. However, antipsychotic drugs do not cause addiction in patients and they do not “cheer up” (make euphoric) the patients.

Another misconception about the antipsychotic agents is that they control the mind by acting as some sort of “chemical straight jacket”. Nevertheless, administered in appropriate doses, the antipsychotic drugs do not “knock out” the patient and do not deprive the patient of the ability of independent thinking. Some antipsychotic drugs may also have sedative and drowsy effects, which can be useful at the beginning of the treatment, in particular if the patient is very agitated. The dose can be adjusted or the therapy can be switched to another drug, when proper control of symptoms is reached.

Medication treatment is the basis of the schizophrenia treatment and the most effective method of controlling disease symptoms which allow the patients to begin other forms of treatment and rebuild their life.

  • References

    1. APA Clinical Guidelines. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. 2004
    2. Falkai P et al. World J Biol Psychiatry 2005; 6: 132-191.
    3. Kendler KS et al. Arch Gen Psychiatry 1996; 53: 1022-1031.
    4. World Health Organization. The World Health Report: 2001: Mental health: new understanding, new hope.
    5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition Text Revision (DSM-IV-TR). Arlington: American Psychiatric Publishing Inc. 2000.
    6. Lieberman JA et al. J Clin Psychiatry 1996; 57(suppl 9): 5-9.
    7. Breier A et al. Am J Psychiatry 1994; 151: 20-26.
    8. Robinson DG et al. Am J Psychiatry 1999; 156: 544-549.
    9. National Institute for Clinical Excellence. National Clinical Practice Guidelines Number 82.
    10. Howard R et al. Am J Psychiatry 2000; 157: 172-178.
    11. Angermeyer MC et al. Schizophr Bull 1990; 16: 293-307.
    12. Murray RM and Fearon P. J Psychiatr Res 1999; 33: 497-499.
    13. Lang UE et al. Cell Physiol Biochem 2007; 20: 687-702.
    14. Harrigan SM et al. Psychol Med 2003; 33: 97-110.
    15. Bottlender R et al. Schizophr Res 2003; 62: 37-44.
    16. Lynn Starr h. et al: Comparison of long-acting and oral antipsychotic treatment effects in patients with schizophrenia, comorbid substance abuse, and a history of recent incarceration: An exploratory analysis of the PRIDE study; Schizophr Res. 2018 Apr;194:39-46. doi: 10.1016/j.schres.2017.05.005. Epub 2017 Jun 7
    17. Awad AG et al. Pharmacoeconomics 2008; 26: 149-162.
    18. Keith SJ et al. Psychiatr Serv 2004; 55: 997-1005.
    19. Lieberman JA et al. Pharmacol Rev 2008; 60: 358-403.
    20. Tandon R et al. Psychoneuroendocrinology 2003; 28(suppl 1): 9-26.
    21. Wyatt RJ. Schizophr Bull 1991; 17: 325–351
    22. Robinson DG et al. Arch Gen Psychiatry 1999; 56: 241-247.
    23. Weiden PJ et al. Psychiatr Serv 2004; 55: 886-891.
    24. Koen L et al. Psychosomatics 2007; 48: 128-134.
    25. Novick D et al. Psychiatry Res 2010; 176: 109-113.
    26. Kozma CM et al. Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate. Current Medical Research and Opinion. 2011.27;1603-1611

show more